Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Optimizing Care Transitions in Multiple Myeloma: Bridging Academic and Community Practices for Bispecific Antibody Therapy : Episode 7

Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care

October 25, 2024
By Cesar Rodriguez Valdes, MD
Binod Dhakal, MD, MS
  • Appalanaidu Sasapu MD, FACP
  • Leo Shunyakov, MD

Opinion
Video

Panelists discuss how transitioning patients with multiple myeloma from community to academic settings faces challenges including communication gaps, differences in treatment approaches, patient reluctance, and logistical hurdles.

EP: 1.The Power of Partnership: Enhancing Patient Care in Multiple Myeloma through Academic and Community Physician Collaboration

EP: 2.Fast-Tracking Care: Streamlining Referrals for Quicker Treatment in Multiple Myeloma

EP: 3.Collaborative Care vs. Independent Treatment: Does It Impact Patient Outcomes in Multiple Myeloma?

EP: 4.Overcoming Challenges in Patient Referrals: Handling Reluctance and Navigating Barriers to Academic Care

EP: 5.When Is the Right Time? Navigating Key Moments for Referring Multiple Myeloma Patients to an Academic Center

EP: 6.Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care

Now Viewing

EP: 7.Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care

EP: 8.Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled

EP: 9.Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies

EP: 10.Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients

EP: 11.Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma

EP: 12.Protocols for Monitoring and Managing Long-Term Complications of Bispecific Therapy in Mutlplie Myeloma

EP: 13.Enhancing Communication Between Academic and Community Oncologists During Referral and Treatment in Multiple Myeloma.

EP: 14.Optimizing Patient Reintegration into Community Care Post-Academic Treatment of Bispecifics in Multiple Myeloma

EP: 15.Unmet Needs and Future Directions for Enhancing Bispecific Therapy Care Transitions in Multiple Myeloma

Video content above is prompted by the following:

  • What are some challenges you are seeing when transitioning from community to academic settings

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 KOLs are featured in this series.
Related Content

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 17th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 17th 2025
Podcast

In unweighted analyses, significant PFS improvements were observed, highlighting the differences in restricted mean survival time of 6.95 months.

Elranatamab and MagnetisMM-3 Results Are Superior to Real-World Multiple Myeloma Outcomes

Tim Cortese
September 17th 2025
Article

1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
September 17th 2025
Podcast

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma

Russ Conroy
September 17th 2025
Article

Therapy with anti-CD38 monoclonal antibodies significantly increased the minimal residual disease–negative rate.

Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma

Tim Cortese
September 17th 2025
Article
Related Content

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 17th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 17th 2025
Podcast

In unweighted analyses, significant PFS improvements were observed, highlighting the differences in restricted mean survival time of 6.95 months.

Elranatamab and MagnetisMM-3 Results Are Superior to Real-World Multiple Myeloma Outcomes

Tim Cortese
September 17th 2025
Article

1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
September 17th 2025
Podcast

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma

Russ Conroy
September 17th 2025
Article

Therapy with anti-CD38 monoclonal antibodies significantly increased the minimal residual disease–negative rate.

Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma

Tim Cortese
September 17th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.